These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26504384)

  • 21. Lactoferrin increases both resistance to Salmonella typhimurium infection and the production of antibodies in mice.
    Drago-Serrano ME; Rivera-Aguilar V; Reséndiz-Albor AA; Campos-Rodríguez R
    Immunol Lett; 2010 Nov; 134(1):35-46. PubMed ID: 20727369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
    Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis.
    Singodia D; Khare P; Dube A; Talegaonkar S; Khar RK; Mishra PR
    J Biomed Nanotechnol; 2011 Feb; 7(1):123-4. PubMed ID: 21485834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming T. gondii infection and intracellular protein nanocapsules as biomaterials for ultrasonically controlled drug release.
    Aw MS; Paniwnyk L
    Biomater Sci; 2017 Sep; 5(10):1944-1961. PubMed ID: 28776612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and evaluation of alginate-chitosan nanocapsules for controlled release of acetamiprid.
    Kumar S; Chauhan N; Gopal M; Kumar R; Dilbaghi N
    Int J Biol Macromol; 2015 Nov; 81():631-7. PubMed ID: 26321424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibitory effect of bovine lactoferrin on Toxoplasma gondii tachyzoites in murine macrophages: role of radical oxygen and inorganic nitrogen oxide in Toxoplasma growth-inhibitory activity.
    Tanaka T; Omata Y; Narisawa M; Saito A; Shimazaki K; Igarashi I; Hirumi H; Suzuki N
    Vet Parasitol; 1997 Jan; 68(1-2):27-33. PubMed ID: 9066048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
    Sordet F; Aumjaud Y; Fessi H; Derouin F
    Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model.
    Gualdi L; Mertz S; Gomez AM; Ramilo O; Wittke A; Mejias A
    Antiviral Res; 2013 Aug; 99(2):188-95. PubMed ID: 23735300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
    Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
    Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite-host interaction.
    Anand N; Kanwar RK; Dubey ML; Vahishta RK; Sehgal R; Verma AK; Kanwar JR
    Drug Des Devel Ther; 2015; 9():3821-35. PubMed ID: 26251568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis.
    Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A
    Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites.
    Tanaka T; Omata Y; Saito A; Shimazaki K; Yamauchi K; Takase M; Kawase K; Igarashi K; Suzuki N
    Exp Parasitol; 1995 Dec; 81(4):614-7. PubMed ID: 8543005
    [No Abstract]   [Full Text] [Related]  

  • 33. Twenty-five years of research on bovine lactoferrin applications.
    Tomita M; Wakabayashi H; Shin K; Yamauchi K; Yaeshima T; Iwatsuki K
    Biochimie; 2009 Jan; 91(1):52-7. PubMed ID: 18585434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin.
    Omata Y; Satake M; Maeda R; Saito A; Shimazaki K; Yamauchi K; Uzuka Y; Tanabe S; Sarashina T; Mikami T
    J Vet Med Sci; 2001 Feb; 63(2):187-90. PubMed ID: 11258458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin.
    Dzitko K; Dziadek B; Dziadek J; Długońska H
    Pol J Microbiol; 2007; 56(1):25-32. PubMed ID: 17419186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice.
    Sfeir RM; Dubarry M; Boyaka PN; Rautureau M; Tomé D
    J Nutr; 2004 Feb; 134(2):403-9. PubMed ID: 14747680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice.
    Morishita S; Ono T; Fujisaki C; Ishihara Y; Murakoshi M; Kato H; Hosokawa M; Miyashita K; Sugiyama K; Nishino H
    J Oleo Sci; 2013; 62(2):97-103. PubMed ID: 23391533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The detection of bovine lactoferrin binding protein on Toxoplasma gondii.
    Tanaka T; Abe Y; Kim WS; Xuan X; Nagasawa H; Igarashi I; Kumura H; Shimazaki K
    J Vet Med Sci; 2003 Dec; 65(12):1377-80. PubMed ID: 14709832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant
    Czarnewski P; Araújo ECB; Oliveira MC; Mineo TWP; Silva NM
    Front Cell Infect Microbiol; 2017; 7():142. PubMed ID: 28487847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.